Market closedNon-fractionalADR
Opthea/OPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Opthea
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Ticker
OPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Business Services
Headquarters
Melbourne, Australia
Employees
-
Website
opthea.com
Opthea Metrics
BasicAdvanced
$224M
Market cap
-
P/E ratio
-$2.48
EPS
0.57
Beta
-
Dividend rate
Price and volume
Market cap
$224M
Beta
0.57
52-week high
$4.40
52-week low
$1.60
Average daily volume
0.45
Financial strength
Current ratio
5.104
Interest coverage (TTM)
-29.64%
Management effectiveness
Return on assets (TTM)
-100.84%
Return on equity (TTM)
-3,383.08%
Return on investment (TTM)
-116.05%
Valuation
Price to revenue (TTM)
1,914.459
Growth
Revenue change (TTM)
127.07%
Earnings per share change (TTM)
0.81%
3-year revenue growth
22.44%
What the Analysts think about Opthea
Analyst Ratings
Majority rating from 5 analysts.
Opthea Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$96M
46.94%
Profit margin
0.00%
NaN%
Opthea Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 22
Q4 23
Q2 23
Q4 24
Q2 24
Actual
-$1.74
-$1.97
-$1.86
-$1.30
-
Expected
-$0.19
-$0.13
-$0.24
-$0.84
-$1.14
Surprise
824.32%
1,413.85%
678.68%
54.18%
-
Opthea News
AllArticlesVideos
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
GlobeNewsWire·2 weeks ago
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
GlobeNewsWire·3 weeks ago
Opthea Announces Placement and Partially Underwritten Entitlement Offer to Raise up to Approximately A$227.3 million (US$150.0 million¹)
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Opthea stock?
Opthea (OPT) has a market cap of $224M as of July 06, 2024.
What is the P/E ratio for Opthea stock?
The price to earnings (P/E) ratio for Opthea (OPT) stock is 0 as of July 06, 2024.
Does Opthea stock pay dividends?
No, Opthea (OPT) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Opthea dividend payment date?
Opthea (OPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Opthea?
Opthea (OPT) has a beta rating of 0.57. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Opthea stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.